Ticker Details
Brainstorm Cell Therapeutics Inc. Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company develops novel adult stem cell therapies for debilitating neurodegenerative disorders such as ALS, MS, and PD among others.
IPO Date:	November 1, 2003
Sector:	Healthcare
Industry:	Biotech
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.11 | 3.57%
Avg Daily Range (30 D):	$0.04 | 4.84%
Avg Daily Range (90 D):	$0.04 | 5.48%

Institutional Daily Volume
Avg Daily Volume:	.28M
Avg Daily Volume (30 D):	.01M
Avg Daily Volume (90 D):	.02M

Trade Size
Avg Trade Size (Sh.):	262
Avg Trade Size (Sh.) (30 D):	644
Avg Trade Size (Sh.) (90 D):	822

Institutional Trades
Total Institutional Trades:	43
Avg Institutional Trade:	$2.23M
Avg Institutional Trade (30 D):	$.62M
Avg Institutional Trade (90 D):	$.62M
Avg Institutional Trade Volume:	.03M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$3.72M
Avg Closing Trade (30 D):	$M
Avg Closing Trade (90 D):	$M
Avg Closing Volume:	29.88K

News

May 15, 2026 @ 8:05 PM BrainStorm Cell Therapeutics Announces First Quart... Source: Brainstorm Cell Therapeutics Inc.

Mar 31, 2026 @ 8:01 PM BrainStorm Cell Therapeutics Announces Full Year 2... Source: Prnewswire

Feb 26, 2026 @ 11:22 AM Brainstorm Cell Therapeutics Secures Second $1 Mil... Source: Prnewswire

Feb 20, 2026 @ 11:00 AM Brainstorm Cell Therapeutics Announces $1 Million ... Source: Prnewswire

Aug 14, 2025 @ 11:02 AM BrainStorm Cell Therapeutics Announces Second Quar... Source: Prnewswire

Financials
	TTM	Q2 2025	Q1 2025
Basic EPS		$-.34	$-.45
Diluted EPS		$-.34	$-.45
Revenue
Gross Profit
Net Income / Loss		$-2.9M	$-2.86M
Operating Income / Loss		$-2.57M	$-3.09M
Cost of Revenue
Net Cash Flow		$M	$M
PE Ratio

Splits
Oct 01, 2024	1:15
Sep 16, 2014	1:15
Aug 13, 2003	2:1